Comparison of different prognostic scores for patients with cirrhosis hospitalized with SARS-CoV-2 infection.

INTRODUCTION AND OBJECTIVES: Viral infections have been described to increase the risk of decompensation in patients with cirrhosis. We aimed to determine the effect of SARS-CoV-2 infection on outcome of hospitalized patients with cirrhosis and to compare the performance of different prognostic models for predicting mortality. PATIENTS: We performed a prospective cohort study including 2211 hospitalized patients with confirmed SARS-CoV-2 infection from April 15, 2020 through October 1, 2020 in 38 Hospitals from 11 Latin American countries. We registered clinical and laboratory parameters of patients with and without cirrhosis. All patients were followed until discharge or death. We evaluated the prognostic performance of different scoring systems to predict mortality in patients with cirrhosis using ROC curves. RESULTS: Overall, 4.6% (CI 3.7-5.6) subjects had cirrhosis (n = 96). Baseline Child-Turcotte-Pugh (CTP) class was assessed: CTP-A (23%), CTP-B (45%) and CTP-C (32%); median MELD-Na score was 19 (IQR 14-25). Mortality was 47% in patients with cirrhosis and 16% in patients without cirrhosis (P < .0001). Cirrhosis was independently associated with death [OR 3.1 (CI 1.9-4.8); P < .0001], adjusted by age, gender, and body mass index >30. The areas under the ROC curves for performance evaluation in predicting 28-days mortality for Chronic Liver Failure Consortium (CLIF-C), North American Consortium for the Study of End-Stage Liver Disease (NACSELD), CTP score and MELD-Na were 0.85, 0.75, 0.69, 0.67; respectively (P < .0001). CONCLUSIONS: SARS-CoV-2 infection is associated with elevated mortality in patients with cirrhosis. CLIF-C had better performance in predicting mortality than NACSELD, CTP and MELD-Na in patients with cirrhosis and SARS-CoV-2 infection. Clinicaltrials.gov:NCT04358380.

Prospective Latin American cohort evaluating outcomes of patients with COVID-19 and abnormal liver tests on admission.

INTRODUCTION & OBJECTIVES: The independent effect of liver biochemistries as a prognostic factor in patients with COVID-19 has not been completely addressed. We aimed to evaluate the prognostic value of abnormal liver tests on admission of hospitalized patients with COVID-19. MATERIALS & METHODS: We performed a prospective cohort study including 1611 hospitalized patients with confirmed SARS-CoV-2 infection from April 15, 2020 through July 31, 2020 in 38 different Hospitals from 11 Latin American countries. We registered clinical and laboratory parameters, including liver function tests, on admission and during hospitalization. All patients were followed until discharge or death. We fit multivariable logistic regression models, further post-estimation effect through margins and inverse probability weighting. RESULTS: Overall, 57.8% of the patients were male with a mean age of 52.3 years, 8.5% had chronic liver disease and 3.4% had cirrhosis. Abnormal liver tests on admission were present on 45.2% (CI 42.7-47.7) of the cohort (n = 726). Overall, 15.1% (CI 13.4-16.9) of patients died (n = 244). Patients with abnormal liver tests on admission presented higher mortality 18.7% (CI 15.9-21.7), compared to those with normal liver biochemistries 12.2% (CI 10.1-14.6); P < .0001). After excluding patients with history of chronic liver disease, abnormal liver tests on admission were independently associated with death [OR 1.5 (CI 1.1-2.0); P = 0.01], and severe COVID-19 (2.6 [2.0-3.3], P < .0001), both adjusted by age, gender, diabetes, pneumonia and body mass index >30. CONCLUSIONS: The presence of abnormal liver tests on admission is independently associated with mortality and severe COVID-19 in hospitalized patients with COVID-19 infection and may be used as surrogate marker of inflammation. CLINICALTRIALS.GOV: NCT04358380.

Impacto en la calidad de vida por la asociación entre trastornos de sueño y síndrome de intestino irritable / Impact on the Quality of Life of the Association between Sleep Disorders and Irritable Bowel Syndrome

Objetivos: determinar si la presencia de alteraciones del sueño se asocia con el deterioro en la calidad de vida, medida a través del cuestionario SF-36, en pacientes con síndrome de intestino irritable (SII). Métodos: se diseñó un estudio de corte transversal en el que se incluyeron individuos con SII seleccionados con los criterios de Roma III, a los que se les aplicó la escala de Epworth, el cuestionario de Pittsburgh y los criterios para síndrome de piernas inquietas (SPI); de manera simultánea, se les realizó la evaluación de calidad de vida usando la escala SF-36. Resultados: se incluyeron 80 pacientes con SII, la mayoría mujeres; el 81% presentó algún tipo de trastorno del sueño determinado por la alteración en 1 o más escalas. Al estratificar los pacientes con y sin trastornos del sueño, se observó que el subgrupo con trastorno del sueño se asoció con mayores alteraciones en la calidad de vida, con OR 4,8125, IC 95%: 1,17-19,02, p < 0,0076, diferencia estadísticamente significativa. Conclusiones: en este estudio se encontró que hasta un 81% de los pacientes con SII presentan trastornos de sueño, y que las alteraciones del sueño en pacientes con SII se asocian con un mayor compromiso de la calidad de vida según la escala SF-36.

Objectives: The objectives of this study were to determine if sleep disorders in patients with irritable bowel syndrome (IBS) were associated with impaired quality of life as measured by the SF36 questionnaire. Methods: This is cross-sectional study in which individuals with IBS according to the Rome III criteria were evaluated for sleep disorders with the Epworth Sleepiness Scale questionnaire and the Pittsburgh Sleep Quality Index (PSQI) questionnaire. They were also evaluated for restless legs syndrome (RLS) and, simultaneously, the Short Form (36) Health Survey was used to evaluate participants’ quality of life. Results: Eighty patients with IBS, mostly women, were included in this study. 81% had some type of specific sleep disorder as measured by at least one of the questionnaires. Patients were groups into those who had sleep disorders, and those who did not. The group which had sleep disorders had statistically significantly more alterations in quality of life (OR 4.8125, 95% CI: 1.17 to 19.02, p <0.0076). Conclusions: This study found that up to 81% of IBS patients have sleep disorders and that sleep disturbances in patients with IBS are associated with decreased quality of life according to the SF36 scale.